Why the study?
Does atorvastatin upregulate nitric oxide synthases and alter Rho-kinase and Akt activity in the kidney of spontaneously hypertensive rats?
Does atorvastatin upregulate nitric oxide synthases and alter Rho-kinase and Akt activity in the kidney of spontaneously hypertensive rats?
Atorvastatin reduces blood pressure and upregulates eNOS and nNOS expressions with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats, providing mechanistic insight into its renoprotective effects.
May inform statin pleiotropy in hypertensive models; hypothesis-generating and requires human validation before clinical consideration.
OBJECTIVE: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, statins reduce blood pressure and have beneficial effects in cardiovascular and kidney diseases. The present study examined the effect of chronic treatment with atorvastatin (ATV) on the expression of nitric oxide synthase (NOS) and the activity of Rho-kinase and Akt in the kidney of spontaneously hypertensive rats (SHRs). METHODS: SHRs were treated with ATV for 8 weeks and the SBP was measured. The expressions of endothelial, neuronal and inducible NOS (eNOS, nNOS and iNOS, respectively) proteins in the kidney were examined by immunoblot analysis. The activity of eNOS, Rho-kinase and Akt in the kidney was examined by assessing the phosphorylation of eNOS, ezrin/radixin/moesin (ERM) and Akt, respectively. RESULTS: ATV reduced the SBP without changing the plasma cholesterol levels. ATV increased eNOS expression in the cortex and medulla and nNOS expression in the medulla, whereas it did not affect iNOS expression. Although it upregulated eNOS expression in the kidney, ATV decreased the levels of phosphorylated eNOS in the cortex and did not affect the ratio of phosphorylated eNOS to total eNOS in the medulla. ATV also inhibited Rho-kinase activity and enhanced Akt activity in the kidney of SHRs. CONCLUSION: ATV upregulates eNOS and nNOS expressions with Rho-kinase inhibition and Akt activation in the kidney of SHRs. The renal nitric oxide system, Rho-kinase and Akt may contribute to the antihypertensive and renoprotective effects of statins.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: